• Publications
  • Influence
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid
TLDR
An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials.
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
TLDR
Cytogenetic risk status is a significant factor in predicting response of AML patients to therapy; however, to tighten treatment correlates within genetically defined AML subsets, a significantly larger leukemia cytogenetic database is warranted.
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.
TLDR
Compared with nonallogeneic SCT therapies, allogeneicSCT has significant RFS and overall survival benefit for intermediate- and poor-risk AML but not for good- risk AML in first complete remission.
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
TLDR
MDR1 is less frequent in younger AML patients, which may in part explain their better response to therapy and neither MRP1 nor LRP are significant predictors of outcome in this patient group, so inclusion of MDR1-modulators alone may benefit younger AMl patients with MDR 1(+) disease.
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
TLDR
Cytogenetic risk status is a significant factor in predicting response of AML patients to therapy; however, to tighten treatment correlates within genetically defined AML subsets, a significantly larger leukemia cytogenetic database is warranted.
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
TLDR
It is indicated that addition of CsA to an induction and consolidation regimen containing infusional DNR significantly reduces resistance to DNR, prolongs the duration of remission, and improves overall survival in patients with poor-risk AML.
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.
TLDR
In this study, the addition of GO to induction or postconsolidation therapy failed to show improvement in CR rate, disease-free survival, or overall survival.
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.
TLDR
Results indicate that mutations in FLT3, RAS, or TP53 are common in older patients with AML and are associated with specific AML phenotypes as defined by laboratory values, cytogenetics, and clinical outcomes.
Acute Myeloid Leukemia in the Elderly : Assessment of Multidrug Resistance ( MDR 1 ) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy
TLDR
AML in the elderly is associated with an kemic blasts were karyotyped and were also analyzed for increased frequency of unfavorable cytogenetics and MDR1 intrinsic drug resistance by quantitating expression of the expression, both of which independently contribute to poor multidrug resistance glycoprotein MDR 1 and functional drug outcomes.
Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.
TLDR
After accounting for the variation among karyotype groups, age was not a significant prognostic factor for OS or RFS, highlighting cytogenetics as the most important prognostic factors in adult ALL.
...
1
2
3
4
5
...